🇺🇸 FDA
Pipeline program

SDREGN2810

R2810-ONC-1763

Phase 2 small_molecule terminated

Quick answer

SDREGN2810 for Advanced Non-Small Cell Lung Carcinoma is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Advanced Non-Small Cell Lung Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials